NDA 221198 is the FDA application for ATEBRIOZ (zilurgisertib). The FDA's Orange Book lists the applicant of record as MIRUM PHARMACEUTICALS INC and the first approval on it as Sep 25, 2026. Code name used in development: INCB000928. Owner today: Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM).
Page updated Nov 19, 2026. FDA records: Drugs@FDA NDA 221198 · Orange Book NDA 221198
| Brand name (FDA) | ATEBRIOZ Orange Book trade name: ATEBRIOZ |
|---|---|
| Active ingredient (FDA) | ZILURGISERTIB FUMARATE |
| Code name | INCB000928 Source: Incyte press release, May 25, 2023 “Phase 1/2 Study of the Activin Receptor-Like Kinase (ALK)-2 Inhibitor Zilurgisertib (INCB000928, LIMBER-104)” |
| FDA applicant of record | MIRUM PHARMACEUTICALS INC FDA Orange Book data files as of Nov 13, 2026 |
|---|---|
| Owner today | Mirum Pharmaceuticals, Inc. (MIRM) Source: Mirum Pharmaceuticals and Incyte press release, Sep 25, 2026 “Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced” |
| Earlier / partner | Incyte (INCY): licensed the drug to the current owner Source: Mirum Pharmaceuticals and Incyte press release, Sep 25, 2026 “Atebrioz was developed by Incyte and licensed to Mirum Pharmaceuticals, Inc. for worldwide development and commercialization.” … “Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced” |
| No. | Trade name | Form; route | Strength | Approved |
|---|---|---|---|---|
| 001 | ATEBRIOZ | TABLET;ORAL | EQ 25MG BASE | Sep 25, 2026 |
Drug page: /drug/atebrioz
Orange Book data: FDA Orange Book data files, as of Nov 13, 2026. Approval dates are the FDA's dates for each product; a later supplement (a new use) does not change them.